A Contract Development and Manufacturing Organisation (CDMO), providing the pharmaceutical industry with a comprehensive range of services.
Arcinova is focused on process, research, development, scale-Up and small-scale manufacturing, including bioanalysis, DMPK, regulatory and consulting services, covering drug candidates in development and launched to the market.
We have majority ownership of this company and serve as MD/Chairman and FD to shape and implement strategy to drive rapid growth. The ex-Covance Alnwick site was acquired in February 2016 and we have set a new strategy and market position, restructured and recruited to add capabilities and are now driving accelerated growth and class leading profitability with substantial business bid and won.
A combustion technology design, fabrication and installation company, with significant proprietary technology, focused on industrial sales worldwide.
Leaders in combustion system design and technology, KFS was created in 1999 by some of the industry’s finest and most forward-thinking engineers and industry experts.
Its distinctiveness is based on the mastery of Computational Fluid Dynamics for burner design and system analysis, backed up by an extensive history of physical modelling.
We held a minority equity interest and provided Chair and FD as directors of the company.
Granted the Queen's Award for Enterprise: International Trade in 2014, we demonstrated periods of sustained growth with high double-digit growth rates and good productivity and profit.
The business was divested in December 2018 for an excellent return.
A design engineering and modelling business with proprietary technology and extensive chemical/biochemical engineering experience.
BPE was formed in 1997 as an independent process engineering consultancy specialising in front-end engineering design for the global life science and specialties industries.
Since then, it has grown year on year, its success based upon strong partnerships with clients in the UK and Europe.
We held a minority equity position and provide Chairman and FD. We reset the strategic focus and designed and implemented a strategy and structure that is resilient to the ebb and flow of demand.
The business was successfully divested in 2020 giving a 5-fold return.
The aim of Nottingham University's Synthetic Biology Centre is to enable the sustainable production of carbon-based chemicals and fuels.
SBRC’s ambition is to combine expertise from a variety of academic disciplines, including green chemistry, biology and computational sciences, to create optimised chassis to allow the replacement of petrochemical derived commodity compounds, utilise waste GHG, alleviate climate change and facilitate wealth creation through the emerging waste economy.
The centre is recruiting internationally to secure the best brains, and wants to establish international recognition as a leading Research Centre with Industrialisation ambitions. We helped the University shape its strategy and proposal to successfully secure £15.4million of BBSRC funding to establish the multidisciplinary Research Centre at the University.
The centre was launched in 2013 when Ian Shott became Chairman of the Strategic Advisory Board and now has more than 120 top level scientists engaged. It is rapidly developing game-changing technology some of which is already being used commercially.
Biocatalysts is a global biotechnology company producing speciality enzymes at commercial scales.
An already profitable business, we helped them look at how to grow the business and improve Executive Management and accounting and restructure the shareholder base.
Subsequently, the company expanded manufacturing capacity and continued to grow, with a well-developed 5-year plan. This facilitated its acquisition by Brain AG.
Chemoxy is one of the largest independent contract chemical manufacturers in Europe.
Working with the Board, we evaluated external market opportunities and internal capabilities and helped prepare a measured and credible growth plan and provided a platform for investment by the Business Growth Fund despite difficult market conditions in their core Oil & Gas sector.
The business was subsequently acquired by Novasep SAS in 2017 then rebranded as SEQENS in 2019.
Sanofi is the world's 5th largest drug company by prescription sales.
We were engaged to provide a science-based legacy of employment for the Fawdon site that they were vacating. We created a masterplan to repurpose the site as a life science business park to accommodate a portfolio of start-up and early growth businesses.
We secured interest from over a dozen such businesses and then moved to help market the site to potential acquisitors, culminating in a successful transaction.
Epigem is a polymer micro engineering company applying complex technologies to the life sciences and electronics industries, specialising in the development and manufacture of microfluidic devices.
We worked on a retainer base, provided an Interim CEO, developed a new strategy and 5-year business plan, instigated monthly board meetings and management accounts and dashboards and designed a new organisation structure focused on generating cash.
In 2013, they secured over £2million of funding for a number of high-tech projects to accelerate the company’s growth in healthcare markets.
We created Excelsyn, a business offering process research, development and scale up of drug substance manufacture to the global pharmaceutical and biotechnology industry, around the acquisition of a Great Lakes Fine Chemicals site in June 2004.
We grew the business rapidly, received backing from 2 VCs and then sold the company to AMRI.
GXPi is a provider of specialist consulting services to help life science organisations achieve their compliance goals.
We advised on strategy, then moved to the equity stage, which then progressed to exit and acquisition by a Scandinavian consultancy.
